You are here

Article Text

Article menu
Download PDFPDF
Commentary
Pembrolizumab plus lenvatinib for all advanced endometrial cancer? Maybe not

http://dx.doi.org/10.1136/ijgc-2022-003419

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    PDF extract preview

    You do not have access to the full text of this article, the first page of the PDF of this article appears above.

    Footnotes

    • Contributors EP is the sole contributor.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests EP works as an internal expert for GSK.

    • Provenance and peer review Not commissioned; internally peer reviewed.